Lee Moore, MD
Cornea and External Diseases Specialist · Madison, MSNPI 1699156950
Payments from drug & device makers
Across 201 payments — averaging $84.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$9K
- Glaukos Corporation$4K
- Oyster Point Pharma, Inc.$904
- Johnson & Johnson Surgical Vision, Inc.$855
- Bausch & Lomb Americas Inc.$652
- AbbVie$603
- plus $1K from 16 others
What the payments were for
- Consulting fees$9,00053%
- Speaking & faculty fees$2,03212%
- Food & beverage$5,86935%
- Education$800%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 5 | $9,162 |
| Glaukos Corporation | 33 | $3,505 |
| Oyster Point Pharma, Inc. | 31 | $904 |
| Johnson & Johnson Surgical Vision, Inc. | 16 | $855 |
| Bausch & Lomb Americas Inc. | 24 | $652 |
| AbbVie(2 entities) | 29 | $603 |
| Biotissue Holdings Inc. | 8 | $349 |
| Novartis | 14 | $198 |
| Mallinckrodt Hospital Products Inc. | 6 | $129 |
| Ocular Therapeutix, Inc. | 5 | $98 |
| Sun Pharmaceutical Industries Inc. | 5 | $93 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $89 |
| Alcon | 5 | $76 |
| Thea Pharma Inc. | 3 | $62 |
| Sight Sciences, Inc. | 3 | $47 |
| Kala Pharmaceuticals, Inc. | 2 | $32 |
| Eyevance Pharmaceuticals LLC | 2 | $27 |
| Aerie Pharmaceuticals, Inc. | 1 | $24 |
| Rayner Intraocular Lenses Limited | 1 | $23 |
| ANI Pharmaceuticals, Inc. | 1 | $21 |
| Tarsus Pharmaceuticals, Inc. | 1 | $19 |
| Amgen | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few cornea and external diseases specialist providers in Mississippito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 601 | $18,749 |
| RestasisCyclosporine | 20 | $17,125 |
| CombiganBrimonidine Tartrate/Timolol | 69 | $16,672 |
| VyzultaLatanoprostene Bunod | 24 | $8,387 |
| MoxifloxacinMoxifloxacin Hcl | 380 | $8,321 |
| Fluorometholone | 115 | $7,798 |
| Alphagan PBrimonidine Tartrate | 16 | $3,388 |
| Loteprednol Etabonate | 25 | $3,130 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 220 | $3,032 |
| Latanoprost | 349 | $2,864 |
| Doxycycline Hyclate | 200 | $2,771 |
| Ketorolac Tromethamine | 147 | $2,716 |
| Acyclovir | 221 | $2,007 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 15 | $1,726 |
| Difluprednate | 17 | $1,647 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Combigan, Alphagan P | $603 | $37,185105 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $652 | $8,38724 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $89 | $3,13025 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cornea and external diseases specialist providers in Mississippion file to place this against a meaningful peer group, so we don't.
Other cornea and external diseases specialist in Madison
- Bo HuangJackson$68K
- Charles McGuffeyJackson$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.